KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gsk (GSK) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to 30.34%.

  • Gsk's EBIT Margin rose 279800.0% to 30.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 25.41%, marking a year-over-year increase of 53900.0%. This contributed to the annual value of 12.82% for FY2024, which is 94200.0% down from last year.
  • Gsk's EBIT Margin amounted to 30.34% in Q3 2025, which was up 279800.0% from 25.33% recorded in Q2 2025.
  • In the past 5 years, Gsk's EBIT Margin ranged from a high of 31.89% in Q1 2022 and a low of 1.99% during Q4 2021
  • In the last 5 years, Gsk's EBIT Margin had a median value of 23.47% in 2021 and averaged 21.97%.
  • In the last 5 years, Gsk's EBIT Margin plummeted by -870700bps in 2021 and then skyrocketed by 279800bps in 2025.
  • Gsk's EBIT Margin (Quarter) stood at 1.99% in 2021, then soared by 1100bps to 23.9% in 2022, then rose by 25bps to 29.89% in 2023, then tumbled by -31bps to 20.57% in 2024, then surged by 48bps to 30.34% in 2025.
  • Its EBIT Margin stands at 30.34% for Q3 2025, versus 25.33% for Q2 2025 and 29.48% for Q1 2025.